53 results about "Lipid vesicle" patented technology

The invention relates to the technical field of biomedical materials, in particular to a mitochondrial transplantation treatment system and application thereof. The mitochondrial transplantation treatment system provided by the invention comprises mitochondria obtained by separation and a transfer vector. Wherein the mitochondria transplantation treatment system is obtained by assembling the mitochondria and the transfer vector, and the transfer vector comprises at least one of artificial lipid vesicles, vesicles derived from cell membranes and exosomes. The preparation process of the mitochondrial transplantation treatment system is simple, healthy mitochondria can be efficiently and rapidly transferred into cells or tissues at the same time, and the mitochondrial function of damaged mitochondrial cells is repaired. The mitochondrial transplantation treatment system has the potential of treating related diseases caused by mitochondrial dysfunction.

The invention relates to the technical field of biology, and particularly discloses an acoustic fluid device and a method for controlling fusion of lipid vesicles through the acoustic fluid device, the device comprises a glass chamber and piezoelectric ceramics attached to the bottom face of the glass chamber, the piezoelectric ceramics are used for generating ultrasonic waves, and the glass chamber serves as a reaction chamber for fusing the lipid vesicles. The method comprises the following steps: determining a lipid vesicle fusion type, and determining vibration frequency and vibration intensity of required ultrasonic waves according to the type; and the piezoelectric ceramics generate ultrasonic waves with required vibration frequency and vibration intensity to act on the glass chamber. According to the invention, the intensity of the sound stream can be randomly and dynamically adjusted, so that the ultrasonic pulse is utilized to induce the sound stream to control the fusion of the lipid vesicles in a non-invasive manner. The method has the advantages of no toxicity, no chemical reagent residue, simple device, no special requirements on the physical properties of the fluid medium and the lipid membrane, non-contact control, good universality, no requirements on the bioprotein receptor on the surface of the lipid membrane and the components of the lipid membrane, and good biocompatibility.

The invention provides a membrane-wrapped organelle-like system for directionally assembling membrane protein, which comprises a molecular framework and a closed lipid bilayer membrane wrapping the outer side of the molecular framework, the molecular framework is loaded with load molecules, the molecular framework directionally recombines the lipid bilayer membrane through a transmembrane region of the membrane protein, and the lipid bilayer membrane is loaded with the load molecules. The lipid bilayer membrane provides a barrier and protection for a molecular framework and loaded molecules, and the lipid bilayer membrane is provided with directional recognition molecules. According to the invention, a molecular framework wrapped by a lipid bilayer membrane is utilized, and a novel technology capable of simulating lipid vesicles of an organelle membrane framework is adopted, so that a brand-new directional delivery function on specific cells or specific organelles in the specific cells can be endowed. And oriented assembly of a membrane protein compound and effective loading of bioactive molecules are realized by using a process of chemically recombining the lipid bilayer membrane.

The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg / mL). In the preferred embodiment the drug in the solubilizing agent is mixed with the liposomes in aqueous suspension so that the concentration of solubilizing agent is lowered to below its capacity to completely solubilize the drug. This results in the drug precipitating but remote loading is capability retained. The process is scalable and the resulting drug-loaded liposomes are characterized by a high drug-to-lipid ratios and predictable drug retention when the liposome encapsulated drug is administered in patients.

The invention relates to a squeezing preparation method of Fuzhuan tea lipid vesicle-like nanoparticles, which comprises the following steps: mixing Fuzhuan tea and ultrapure water in a mass ratio of (1: 6)-(1: 10), squeezing juice, passing through a 100-200-mesh filter screen, and squeezing to obtain a Fuzhuan tea stock solution; then, carrying out gradient centrifugation on the Fuzhuan tea stock solution to obtain supernate; and finally, carrying out centrifugal treatment on the supernatant at a relative centrifugal force higher than the highest relative centrifugal force of gradient centrifugation, and adding a standard phosphate buffer solution with the mass ratio of 1: 8-1: 10 to carry out resuspension precipitation, so as to obtain the Fuzhuan tea lipid vesicle-like nanoparticles. The invention also provides the Fuzhuan tea lipid vesicle-like nanoparticles obtained by using the method and application of the Fuzhuan tea lipid vesicle-like nanoparticles in treatment of ulcerative colitis. According to the invention, the seasonal influence of the preparation of the existing tea lipid vesicle-like nanoparticles is overcome, the cost is greatly reduced, the purity and quality are controllable, the problems of intestinal ecological imbalance such as mucosal epithelium repair, barrier homeostasis and the like can be solved, the safety is good, no side effect is generated, and a potential treatment mode is provided for the treatment of gastrointestinal diseases.

The invention relates to an exosome-like nano-vesicle for gene delivery and a preparation method thereof, the exosome-like nano-vesicle comprises a lipid phase and an inner water phase entrapped in the lipid phase, the lipid phase is prepared from cholesterol, phosphatidyl ethanolamine, phosphatidylserine, phosphatidylcholine and sphingomyelin; the inner water phase comprises nucleic acid drugs. The raw material components of the lipid phase are set, the use of cationic lipid and ionizable lipid is avoided, so that the anionic lipid vesicles simulating exosome lipid components can be prepared, the lipid phase entraps the internal water phase containing nucleic acid drugs, and the lipid vesicles have the characteristics of good stability, low toxicity and high transfection efficiency; the exosome has the advantages of limited immunogenicity, high delivery efficiency and enhancement of stability in the in-vivo circulation process of the natural exosome, the preparation process and the final quality are controllable, and commercialized production and clinical transformation are easier to realize.

The invention discloses a pH-sensitive bionic drug lipid vesicle as well as a preparation method and application thereof. The bionic drug lipid vesicle is a drug-loaded lipid vesicle formed by mixing a cell membrane vesicle and drug-loaded phospholipid and then carrying out self-assembly, the drug-loaded phospholipid is obtained by connecting a drug and distearoyl phosphatidyl ethanolamine-polyethylene glycol (DSPE-PEG) through a pH-sensitive connecting agent cis-aconitic anhydride. The bionic drug lipid vesicle prepared by the invention has excellent pH response capability, can accurately respond to the pH value change of a tumor microenvironment, and realizes tumor targeted release of the drug. The bionic drug lipid vesicle is prepared by adopting a method of ultrasonic self-assembly after physical mixing, the operation is simple, convenient and feasible, and the requirement on process conditions is relatively low.

The present disclosure provides a method for introducing a target molecule into a lipid vesicle (for example, an extracellular vesicle). The present disclosure also provides a lipid vesicle (for example, an extracellular vesicle) produced using the method for introducing a target molecule into a lipid vesicle (for example, an extracellular vesicle). According to the present disclosure, a complex (a first complex) of a lipid (for example, an ionic lipid; particularly a liquid lipid composition) and a target molecule is fused with a lipid vesicle (for example, an extracellular vesicle) to form a complex (a second complex). The first complex and the second complex are suitable for the introduction of the target molecule into a cell, and the second complex is particularly suitable for the introduction of the target molecule into a cell. The target molecule may be a protein (for example, an antibody), a nucleic acid, or other compounds.

The present invention relates to compositions comprising transmembrane stem cell factor (tmSCF) polypeptide embedded in a lipid vesicle and methods of use thereof. In some embodiments, the lipid vesicle is a nanocarrier. Disclosed herein is a method for promoting angiogenesis in a subject, comprising administering to a subject in need thereof an effective amount of a composition comprising a tmSCF polypeptide embedded in a lipid vesicle. Disclosed herein is a method for treating a subject with peripheral vascular disease (PVD), comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a tmSCF polypeptide.

This application relates to a biphasic lipid vesicle pharmaceutical composition comprising a lipid bilayer comprising vesicle-forming lipids, an oil-in-water emulsion stabilized by one or more surfactants, one or more compounds, and one or more penetration enhancers. The one or more penetration enhancers include one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, alone or in combination with one or more penetration enhancers selected from one or more of terpenes, alkaloids, salicylate derivatives, and polycationic surfactants, and combinations thereof. This application also relates to a pharmaceutical composition comprising a biphasic lipid vesicle comprising a lipid bilayer, the biphasic lipid vesicle comprising a vesicle-forming lipid, an oil-in-water emulsion stabilized by one or more polycationic surfactants, and one or more compounds.

The present disclosure relates to compositions comprising phospholipids, lipid vesicles, and / or liposomes, and methods of use thereof. In one aspect, the present disclosure relates to methods and compositions for delivery of, biologically active lipids to reduce microvascular dysfunction and infarct size during revascularization of the blocked artery in a mammalian subject.

The invention relates to the technical field of lipid vesicle preparation, and particularly discloses size and position controllable lipid vesicle preparation equipment and method.The equipment comprises a cavity, a microarray structure and an ultrasonic transducer which are arranged hierarchically; the cavity is used for being filled with a physiological buffer solution; the surface of the microarray structure is provided with micropores with set sizes and positions, and lipid membranes are arranged in the micropores; the ultrasonic transducer emits ultrasonic waves to the microarray structure, the ultrasonic waves induce an array acoustic flow field through the micropore array structure of the microarray structure, and lipid membranes in micropores form spherical lipid vesicles under the combined action of Reynolds stress and the array acoustic flow field. According to the method, lipid vesicle preparation equipment is used for generating an array acoustic flow field to prepare the spherical lipid vesicles. According to the invention, inhibition of sodium chloride in a physiological buffer solution on lipid membrane expansion is broken through, the spherical lipid vesicles with controllable positions and sizes are prepared, and the spherical lipid vesicles are suitable for various lipid membranes.

The disclosure includes systems comprising non-viral DNA vectors encapsulated in lipid vesicles that are designed to achieve sustained therapeutically relevant expression levels in blood plasma of therapeutic proteins, polypeptides, or peptides. The system can express antibodies or antigen-binding fragments at sustained and therapeutically relevant levels. The system can be administered to a subject via local or systemic routes such as intravenous (IV) or intramuscular (IM), and repeat dosing produces an additive effect. For local administration, localized expression can be achieved. Applications span treatments for various conditions, including infectious diseases, cancers, and inflammatory diseases.

A lipid-based coating composition for coating a medical device, wherein the coating composition includes a) lipid vesicles consisting of i. 85-95 mol % of a phospholipid (A) having a phosphatidylcholine group; ii. 5-12 mol % of a PEGylated phospholipid (B); optionally 0-3 mol % of a lipophilic compound (C) other than lipids (A) and (B); b) 0-5 wt. % of a water-soluble additive (D); and c) at least 95 wt. % of water, wherein lipid vesicles having a number average size between 50 and 140 nm (measured according to dynamic light scattering) and wherein the lipid vesicle concentration ranges between 0.025 mg / ml and 2 mg / ml, and wherein the mol % of lipids (A), (B) and (C) is calculated relative to the total molar amount of lipids (A)+(B)+(C) in the lipid-based coating composition and wherein the wt. % of water-soluble additive (D) is calculated relative to the weight of the total composition.

Provided are defined culture media for culturing pluripotent stem cells in a suspension culture devoid of substrate adherence, the defined culture media comprising an effective amount of a protease inhibitor; a GSK3β inhibitor and at least one agent selected from the group consisting of a protease inhibitor and a WNT3A polypeptide; a WNT3A polypeptide and a stabilizing agent thereof with the proviso that said stabilizing agent is not a lipid vesicle; and / or a GSK3β inhibitor, with the proviso that the medium is devoid of an ERK1 / 2 inhibitor. Also provided are cell cultures and methods of suing same.

The invention belongs to the technical field of biology, and particularly relates to a modification method of lipid vesicles, modified lipid vesicles and application of the modified lipid vesicles. The modification method of the lipid vesicles comprises the following steps: S1, mixing a lipid vesicle solution and a liquid organic modifier at 0-60 DEG C to obtain a mixture; s2, fully and uniformly mixing the mixture to enable the modifier and the lipid vesicles to fully act, and standing to obtain a water phase, namely the modified lipid vesicles. According to the method, the delivery efficiency of the lipid vesicles can be improved while the structure and the function of the original lipid vesicles are not influenced. The modified lipid vesicle prepared by the method disclosed by the invention can be used as an ultrasonic synergistic material and has ultrasonic synergistic (radiography and treatment) effects. The modified lipid vesicles prepared by the method disclosed by the invention have stronger permeability, active ingredients carried by the lipid vesicles are favorably delivered to the deep part of a tumor, and the treatment effect is enhanced.

Provided herein are lipid vesicle-coated magnetic beads, and methods of making and using the same.

The cosmetic composition comprises a vesicle concentrate consisting of an aqueous solution of vegetable lipid vesicles or lipid vesicles of plant origin having walls containing phospholipids, phytosphingosine, phytosterols, β-phytosteryl sulfate and optionally other derivatives of phytosterols, and ceramides and / or pseudoceramides, for use in the formulation of cosmetic products for the care of the skin and hair, and for decorative purposes for the face, eyes, eyelashes, lips and body. The vesicle concentrate may also contain lysophospholipids, esters of phytosterols, fatty acids, moisturizers, emollients, active lipophilic molecules, active hydrophilic molecules, thickeners and film-forming molecules. A cosmetic product comprises the vesicle concentrate cosmetic composition and other cosmetically acceptable ingredients.

The present invention provides methods of introducing a molecule of interest into a lipid vesicle, such as an extracellular vesicle. The present invention provides lipid vesicles (e.g., extracellular vesicles) obtained using a method for introducing a molecule of interest into lipid vesicles (e.g., extracellular vesicles). According to the present invention, a complex of a lipid (e.g., an ionic lipid, in particular a liquid lipid composition) and a molecule of interest (a first complex) is fused with a lipid vesicle (e.g., an extracellular vesicle) to form a complex (a second complex). The first complex and the second complex are suitable for introducing a target molecule into a cell, and the second complex is particularly suitable for introducing a target molecule into a cell. The target molecule may be a protein (e.g., an antibody), a nucleic acid, or other compound.

The application belongs to the technical field of medicine, and particularly relates to an anti-HPV earthworm extract delivery body gel and a preparation method and application thereof. The preparation method comprises the following steps: stirring and hydrating earthworm extract and a lipid layer to obtain lipid vesicles, then performing inflation, ultrasonic treatment and extrusion to obtain earthworm extract delivery bodies, and finally adding a carbomer after adjusting pH and uniformly mixing to obtain the anti-HPV earthworm extract delivery body gel. The application improves the inhibitory effect on HPV viruses by compounding the carbomer gel with the earthworm extract delivery body, can promote the shrinkage and death of cervical cancer cells, further improves the viscosity of the earthworm extract delivery body by combining the gel with the earthworm extract delivery body, improves the adhesion of the earthworm extract delivery body and the inner wall of the vagina, and thus improves the effect of preventing and treating HPV virus infection.

Hair treatment compositions are disclosed. In some embodiments, the composition can include a first fraction of lipid vesicles encapsulating a first material and a second fraction of lipid vesicles encapsulating a second, different material. In some embodiments, the first material is a stimulant material, such as caffeine or green tea catechins, and the second material is a botanical bioactive material. The lipid vesicles can be plant-derived extracellular vesicles. In some embodiments, the composition comprises a base material with a non-encapsulated stimulant material and lipid vesicles that encapsulate a botanical bioactive material. The composition can also include three distinct carrier systems: lipid vesicles, liposomes, and ceramide complexes, each encapsulating a different bioactive material. These compositions can be formulated into products such as serums, masks, shampoos, or conditioners, which can be part of a multi-product hair care system.

Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.

The invention belongs to the technical field of plant genetic transformation, and discloses a liposome-mediated maize pollen transfection method. The method comprises the following steps: preparing a plasmid DNA solution and a mixed lipid vesicle SMV solution composed of lecithin and cationic lipid DOTMA, and mixing and incubating the plasmid DNA solution and the mixed lipid vesicle SMV solution according to a mass ratio to form an SMV-DNA compound transfection solution; collecting and pretreating fresh corn pollen, and co-incubating with the transfection solution at low temperature; after drying treatment, the pollen is directly used for pollinating female ears of receptor corn, and transgenic offspring seeds are obtained. According to the method, efficient delivery of exogenous DNA is realized by utilizing affinity and electrostatic interaction of liposome and pollen cell membranes, tissue culture is not needed, the method is independent of genotypes, the method is simple and convenient to operate and low in cost, the problem of somatic cell variation is effectively avoided, the transformation efficiency can reach about 1.4%, and an efficient and practical new technical approach is provided for corn genetic improvement.

Cosmetic composition containing a vesicular concentrate consisting of a water solution of vegetal or of vegetal origin lipid vesicles with walls comprising phospholipids, phytosfingosine, phytosterol, beta-phytosteryl sulfate and optionally other derivatives of phytosterol and ceramides and / or pseudoceramides used for preparing cosmetic products for skin and hair care and for decorating face, eyes, eyelashes, lips and body. Said vesicular concentrate can also comprise a lysophospholipid, ester of phytosterol, fatty acids, humectants, emollients, active lipophilic molecules, active hydrophilic molecules, thickening agents, and film-forming molecules. The cosmetic product contains said vesicular concentrate cosmetic composition and any other cosmetically acceptable ingredient.

A method of inhibiting or reducing the migratory ability of tumour cells in a subject is provided. The method involves administering to the subject a composition including Cripto-positive lipid vesicles, the Cripto protein being displayed on the surface of the Cripto-positive lipid vesicles.

Hair treatment compositions are disclosed. In some embodiments, the composition can include a first fraction of lipid vesicles encapsulating a first material and a second fraction of lipid vesicles encapsulating a second, different material. In some embodiments, the first material is a stimulant material, such as caffeine or green tea catechins, and the second material is a botanical bioactive material. The lipid vesicles can be plant-derived extracellular vesicles. In some embodiments, the composition comprises a base material with a non-encapsulated stimulant material and lipid vesicles that encapsulate a botanical bioactive material. The composition can also include three distinct carrier systems: lipid vesicles, liposomes, and ceramide complexes, each encapsulating a different bioactive material. These compositions can be formulated into products such as serums, masks, shampoos, or conditioners, which can be part of a multi-product hair care system.

The invention relates to a composition for oral or topical human administration and a preparation method thereof. The present invention relates to pentacyclic triterpenoid compounds wherein said triterpenoid compounds are incorporated into lipid vesicles, preferably cream globules, surrounded by three layers of membranes. The triterpenoid is preferably betulinic acid, and / or betulinol, and / or lupenol, and / or oleanolic acid, and / or ursolic acid, most preferably betulinic acid. The incorporation of the triterpenoid compound into the milk fat globules or lipid vesicles at a high payload of at least 10 to at most 50 mg / ml is preferably accomplished with high energy emulsification techniques, most preferably ultrasound treatment. The composition is present as a liquid emulsion formulation in a preferred embodiment. In another preferred embodiment, the composition is a powder, which can be prepared from a liquid embodiment of the composition by, for example, spray drying or freeze drying techniques. The composition can be preferably used as a medicament, a food supplement or a nutraceuticals for the treatment or prevention of cancer, type 2 diabetes, obesity and cardiovascular diseases.

The invention discloses a method for preparing lipoid vesicles by a T-type mixing method, which specifically comprises the following steps: respectively dissolving a nonionic surfactant and cholesterol in absolute ethyl alcohol, and carrying out ultrasonic treatment to completely dissolve the nonionic surfactant and cholesterol; calculating the volume of the required solution according to the mass ratio of the nonionic surfactant to the cholesterol, and uniformly mixing the nonionic surfactant and the cholesterol to obtain a mixed solution; and the mixed solution and distilled water are simultaneously extruded through two inlets in the upper end of the T-shaped mixing pipe respectively, an organic phase is diluted into a water phase, and the polarity of the solvent is increased, so that the nonionic surfactant is aggregated and precipitated, and the lipoid vesicles are obtained at the output end. And ultrasonically reducing the particle size of the obtained lipoid vesicles through an ultrasonic cell crusher. And extruding by using a liposome extruder to obtain the lipoid vesicles with uniform particle size. The preparation method of the lipid vesicles is simple, the requirement on equipment is low, and conditions are easy to control; the obtained lipoid vesicles are small in particle size and good in monodispersity and stability, and can be used for preparing drug-loaded lipoid vesicles.

The invention discloses a method for preparing oleic acid lipid vesicles by using a magnetic stirrer, and relates to the technical field of biology, and the method comprises the following specific steps: S1, dissolving phosphatidylcholine in chloroform to obtain a phosphatidylcholine-chloroform solution, and carrying out vacuum drying on the phosphatidylcholine-chloroform solution in a glass bottle to obtain a lipid membrane; s2, adding a NaOH solution with the pH value of 8-9 into the glass bottle in which the lipid film is formed; s3, adding oleic acid into the mixed solution, heating, keeping constant temperature, and stirring by using a magnetic stirrer to obtain an oleic acid lipid vesicle solution. According to the method, the phosphatidylcholine is dissolved by using chloroform, then the alkaline solution and the oleic acid are added, and stirring is performed in a heating environment, so that the lipid vesicles can be prepared, the whole process is simple, the stirring time is short, and compared with an existing preparation method, the operation difficulty and the equipment cost are reduced.